Table 1.
Baseline characteristics of studied patients
| Variables | Overall (n = 523) | Deceased (n = 153) | Survived (n = 370) | p value |
|---|---|---|---|---|
| Clinical characteristics | ||||
| Age, years | 82.75 ± 2.74 | 83.32 ± 3.11 | 82.55 ± 2.55 | 0.006 |
| Male, n (%) | 329(60) | 109(62) | 220(59) | 0.576 |
| BMI, kg/m2 | 23.77 ± 3.50 | 23.28 ± 3.84 | 23.96 ± 3.34 | 0.078 |
| Smoking, n (%) | 215(40) | 71 (43) | 141 (39) | 0.445 |
| Family history of CAD, n (%) | 55(10) | 22 (13) | 33 (9) | 0.307 |
| Hypertension, n (%) | 409(75) | 134(76) | 275 (74) | 0.671 |
| Diabetes mellitus, n (%) | 221(41) | 85 (49) | 136(37) | 0.005 |
| MI type | ||||
| STEMI | 244(47) | 64(42) | 180(49) | 0.211 |
| NSTEMI | 279(53) | 89(58) | 190(51) | |
| Laboratory test | ||||
| Triglyceride, mmol/L | 1.22 (0.93–1.56) | 1.21 (0.92–1.59) | 1.23 (0.93–1.52) | 0.887 |
| TC, mmol/L | 3.81 ± 0.94 | 3.78 ± 0.93 | 3.82 ± 0.94 | 0.623 |
| HDL-C, mmol/L | 1.09 ± 0.29 | 1.05 ± 0.29 | 1.11 ± 0.29 | 0.052 |
| LDL-C, mmol/L | 2.24 ± 0.78 | 2.20 ± 0.78 | 2.26 ± 0.77 | 0.356 |
| Lipoprotein(a), mg/L | 203.69 (95.98–438.00) | 220.44 (101.04–409.51) | 202.00 (93.92–460.02) | 0.552 |
| Creatinine, μmol/L | 106.86 ± 40.54 | 122.56 ± 50.36 | 100.38 ± 33.71 | < 0.001 |
| hsCRP, mg/L | 4.88 (1.84–11.28) | 8.29 (3.06–12.20) | 4.19 (1.56–10.68) | < 0.001 |
| LVEF (%) | 52.73 ± 10.73 | 49.47 ± 11.86 | 54.29 ± 9.79 | < 0.001 |
| CK-MB, ng/mL | 27.65 ± 58.10 | 30.94 ± 62.07 | 26.26 ± 56.37 | 0.421 |
| Troponin I, ng/mL | 4.86 ± 8.64 | 3.73 ± 6.65 | 7.58 ± 11.73 | < 0.001 |
| Leukocyte parameters | ||||
| Leukocytes, 109/L | 7.42 ± 2.81 | 8.21 ± 4.43 | 7.13 ± 2.41 | < 0.001 |
| Neutrophils, 109/L | 5.28 ± 2.67 | 6.09 ± 3.58 | 4.91 ± 2.09 | < 0.001 |
| Lymphocytes, 109/L | 1.46 ± 0.60 | 1.28 ± 0.57 | 1.53 ± 0.61 | < 0.001 |
| Monocytes, 109/L | 0.48 ± 0.20 | 0.52 ± 0.22 | 0.47 ± 0.18 | 0.013 |
| Eosinophils, 109/L | 0.15 ± 0.17 | 0.12 ± 0.14 | 0.16 ± 0.19 | 0.008 |
| Basophils, 109/L | 0.02 ± 0.02 | 0.02 ± 0.02 | 0.02 ± 0.03 | < 0.001 |
| Neutrophil-to-lymphocyte ratio | 4.58 ± 4.57 | 6.21 ± 6.72 | 3.83 ± 2.86 | < 0.001 |
| Monocyte-to-lymphocyte ratio | 0.38 ± 0.22 | 0.48 ± 0.30 | 0.34 ± 0.17 | < 0.001 |
| NMLR | 4.96 ± 4.73 | 7.15 ± 7.13 | 4.17 ± 2.96 | < 0.001 |
| Eosinophil-to-leukocyte ratio | 0.02 ± 0.03 | 0.02 ± 0.02 | 0.02 ± 0.03 | 0.005 |
| Treatment at admission | ||||
| Aspirin, n (%) | 504(96.2) | 147 (95.5) | 357(96.5) | 0.618 |
| Statin, n (%) | 486(92.7) | 137(89.0) | 349 (94.3) | 0.041 |
| Beta-blocker, n (%) | 479(91.4) | 136(88.3) | 343(92.7) | 0.102 |
| CCB, n (%) | 114(21.8) | 30(19.5) | 84(22.7) | 0.486 |
| ACE-I/ARB, n (%) | 279(53.3) | 69 (45.1) | 210(56.8) | 0.016 |
| Clopidogrel, n (%) | 486(92.7) | 142 (92.2) | 344(93.0) | 0.716 |
| Ticagrelor, n (%) | 32(6.3) | 10(6.5) | 22(5.9) | 0.842 |
| CABG | 5(1.0) | 1(0.6) | 4(1.1) | 1.000 |
| PCI | 228(43.5) | 38(24.7) | 190(51.4) | < 0.001 |
Data were expressed as mean ± SD, median (Q1–Q3 quartiles) or n (%)
BMI body mass index, CAD coronary artery disease, MI myocardial infarction, STEMI ST-segment elevation myocardial infarction, NSTEMI Non-ST-segment elevation myocardial infarction, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, hsCRP high sensitivity C-reactive protein, LVEF left ventricular ejection fraction, NMLR neutrophil-plus-monocyte-to-lymphocyte ratio, CCB calcium channel blockers, ACE-I angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, SD standard deviation